Atlas Trials

Intrinsic Validity of Molecular Marker(s) Detection on Tissular Tumoral DNA to Predict the Efficacy of 177Lutetium-PSMA-617 (Lu-PSMA) Treatment for Castration-resistant Metastatic Prostate Cancer

Clinical trial NCT06600802 · RECRUITING

Trial details

NCT number
NCT06600802
Sponsor
Centre Jean Perrin
Status
RECRUITING
Phase
Not Applicable
Study type
INTERVENTIONAL
Castration-resistant Metastatic Prostate CancerTreated by 177Lutetium-PSMA-617 (Lu-PSMA)
Start date
2024-10-08
Primary completion
2034-06-30
Enrollment
120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.